AOD-9604Cellular PeptideSafety Rating 8/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| LA PeptidesBest $/mgCOA on request | $49.99 | $5.00 | May 14, 2026 | Buy → |
| Evolve PeptidesCOA ✓ · 3POut of stock | $114.75 | $5.74 | Apr 22, 2026 | Buy → |
| Olympex SolutionsCOA ✓ · 3P | $29.99 | $6.00 | Apr 6, 2026 | Buy → |
| Ascension PeptidesCOA ✓ · 3P | $32.49 | $6.50 | Apr 16, 2026 | Buy → |
| Evolve PeptidesCOA ✓ · 3P | $68.00 | $6.80 | Apr 22, 2026 | Buy → |
Overview
About AOD-9604
Mechanism of action
Modified fragment of HGH C-terminus (177–191). Stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic receptors without affecting IGF-1 or blood glucose.
Safety profile
Injection site reactions, headache, redness at injection site. No insulin resistance. Generally very safe. · 6+ RCTs, 900+ participants; no IGF-1 or glucose effects; excellent tolerability; GRAS status in Australia
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops AOD-9604 below your target.
Related pages
More on AOD-9604
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Fragment of the C-terminal region of human GH (amino acids 177–191) that retains lipolytic activity without stimulating IGF-1 production, avoiding growth-promoting side effects.
- Phase IIa 12-week trial (1 mg/day oral, n~300) showed a 2.6 kg weight loss vs 0.8 kg with placebo — but the larger 24-week Phase IIb OPTIONS trial (n=536) failed to meet its primary endpoint, and Metabolic Pharmaceuticals terminated obesity development in March 2007.